Intercept Pharmaceuticals reported $-20321000 in Pre-Tax Profit for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US $ -33.57M 79M
Alnylam Pharmaceuticals ALNY:US $ -274.67M 35.32M
Amarin AMRN:US $ -64.8M 36.45M
Arrowhead Research ARWR:US $ -72.05M 116.41M
AstraZeneca AZN:LN 258259.83M 36783.7M
Biogen BIIB:US $ 874.8M 28.6M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Enanta Pharmaceuticals ENTA:US $ -32.15M 1.44M
Esperion Therapeutics ESPR:US $ -66324000 9.59M
Galectin Therapeutics GALT:US $ -9.61M 0.32M
Intercept Pharmaceuticals ICPT:US $ -20.32M 3.04M
IONIS PHARMACEUT IONS:US $ -103M 39M
Neurocrine Biosciences NBIX:US $ -23.3M 44.7M
Novartis NOVN:VX SF 4129M 217M
Ptc Therapeutics PTCT:US $ -148.7M 26.8M
Sangamo Biosciences SGMO:US $ -43.09M 0.83M
Sarepta Therapeutics SRPT:US $ -228.09M 123.95M